Headquartered in New York with research facilities in Oregon, SIGA is focused to disarming dreaded viral diseases and create robust, modern biodefense countermeasures. Though SBIR funding has been from NIH, the firm has extensive non-SBIR contracts with other federal agencies factoring to many millions of dolars. Triggered by its ongoing litigation with PharmAthene over a 2006 transaction to merge, Inc and the loss of an earlier appeal of a NASDAQ decision, in March 2015 SIGA was notified of its suspension from NASDAQ. As of that decision, the firm now trades on OTC. SIGA Technologies, Inc., formerly known as SIGA Pharmaceutical Inc., specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. The original Phase I SBIR nvolvement was under the name of a PA firm called Viropharma Inc. In 2004, there was agreement between ViroPharma and Siga for the latter to acquire certian assets to include the SBIR award, Siga's business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats.
